Kusindarta Dwi Liliek, Wihadmadyatami Hevi
Department of Anatomy, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia.
Vet World. 2021 Oct;14(10):2588-2595. doi: 10.14202/vetworld.2021.2588-2595. Epub 2021 Oct 5.
Umbilical cord blood (UCB) cells are an important source of mesenchymal stem cells (MSCs). It is known that the umbilical cord is rich in hematopoietic stem cells, which influenced research on ontogeny and transplantation (allogeneic transplantation). In recent years, stem cell research has emerged as an area of major interest due to its prospective applications in various aspects of both human and veterinary medicine. Moreover, it is known that the application of MSCs has several weaknesses. The use of these cells has limitations in terms of tumorigenesis effect, delivery, safety, and variability of therapeutic response, which led to the use of secretomes as an alternative to cell-free therapy. The main obstacle in its use is the availability of human UCB as an origin of MSCs and MSCs' secretomes, which are often difficult to obtain. Ethical issues regarding the use of stem cells based on human origin are another challenge, so an alternative is needed. Several studies have demonstrated that MSCs obtained from bovine umbilical cords have the same properties and express the same surface markers as MSCs obtained from human umbilical cords. Therefore, secretomes from MSCs derived from domestic animals (bovine) can possibly be used in human and veterinary medicine. This finding would contribute significantly to improve cell-free therapy. At present, the use of UCB MSCs derived from domestic animals, especially bovines, is very restricted, and only limited data about bovine UCB are available. Therefore, the aim of this review was to provide an updated overview of cell-free therapy and discuss the new possibilities introduced by the generation of this therapy derived from bovine umbilical MSCs as a promising tool in developing modern and efficient treatment strategies.
脐带血(UCB)细胞是间充质干细胞(MSCs)的重要来源。众所周知,脐带富含造血干细胞,这影响了个体发育和移植(同种异体移植)的研究。近年来,干细胞研究因其在人类和兽医学各个方面的潜在应用而成为一个主要关注领域。此外,已知间充质干细胞的应用存在一些弱点。这些细胞的使用在肿瘤发生效应、递送、安全性和治疗反应的变异性方面存在局限性,这导致使用分泌组作为无细胞治疗的替代方法。其使用的主要障碍是作为间充质干细胞和间充质干细胞分泌组来源的人类脐带血的可用性,而这往往难以获得。基于人类来源的干细胞使用的伦理问题是另一个挑战,因此需要一种替代方法。多项研究表明,从牛脐带获得的间充质干细胞具有与从人类脐带获得的间充质干细胞相同的特性,并表达相同的表面标志物。因此,来自家畜(牛)的间充质干细胞的分泌组可能可用于人类和兽医学。这一发现将对改善无细胞治疗做出重大贡献。目前,来自家畜尤其是牛的脐带血间充质干细胞的使用非常有限,关于牛脐带血的可用数据也很有限。因此,本综述的目的是提供无细胞治疗的最新概述,并讨论由牛脐带间充质干细胞产生的这种治疗方法带来的新可能性,作为开发现代高效治疗策略的一种有前途的工具。